Status:
UNKNOWN
Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type
Lead Sponsor:
Sun Yat-sen University
Conditions:
NK/T Cell Lymphoma Nos
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimen for newly diag...
Eligibility Criteria
Inclusion
- biopsy proved extranodal natural killer/T-cell lymphoma, nasal type;
- newly diagnosed stage III/IV patients;
- at least one evaluable lesion；
- ECOG PS 0-2;
- 18-75 years; without other malignancy;
- proper functioning of the major organs.
Exclusion
- hemophagocytic syndrome or aggressive NK cell leukemia;
- involvement of central nervous system;
- previously received treatment of chemotherapy, radiotherapy, immunotherapy or biotherapy for lymphoma；
Key Trial Info
Start Date :
October 9 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 9 2023
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT04127227
Start Date
October 9 2019
End Date
October 9 2023
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China, 51000